Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists

@article{Kondru2008MolecularIO,
  title={Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists},
  author={Rama Kondru and Jun Zhang and Changhua Ji and Taraneh Mirzadegan and David. Rotstein and Surya Sankuratri and Marianna Dioszegi},
  journal={Molecular Pharmacology},
  year={2008},
  volume={73},
  pages={789 - 800}
}
In addition to being an important receptor in leukocyte activation and mobilization, CCR5 is the essential coreceptor for human immunodeficiency virus (HIV). A large number of small-molecule CCR5 antagonists have been reported that show potent activities in blocking chemokine function and HIV entry. To facilitate the design and development of next generation CCR5 antagonists, docking models for major classes of CCR5 antagonists were created by using site-directed mutagenesis and CCR5 homology… 

Figures and Tables from this paper

Advances of CCR5 antagonists: From small molecules to macromolecules.

Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)*

SDM and automated docking predicted that maraviroc inserts deeply in CCR5 transmembrane cavity where it can occupy three different binding sites, whereas CCL3 and gp120 lie on distinct yet overlapped regions of the C CR5 extracellular loop 2, suggesting that receptor dimerization might represent a target for new CCR4 entry inhibitors.

Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.

The mechanism of action of C CR5 antagonists, how HIV resistance to CCR5 antagonists occurs, and the subsequent effects on Env function are discussed, which may open up new avenues to target CCR7 antagonist resistant viruses.

Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands

The functional analysis of TMP peptides using chemotactic migration assay showed that both peptides did not mediate the migration of responsive cells, indicating that TMP-1 and T MP-2 represent promising CCR5 targeting peptide candidates.

In-silico Modeling of Chemokine Receptor CCR2 And CCR5 to Assist the Design of Effective and Selective Antagonists

The success stories of combined receptor modeling/mutagenesis approach to probe the allosteric nature of chemokine receptor binding by small molecule antagonists for CCR2 and CCR5 using Rhodopsin as template are reviewed.

Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study

Three-dimensional models based on a closer homolog with higher resolution of CCR2/CCR5 and PROCHECK results indicated that the models were reasonable, and can be a starting point for further structure-based drug design.

New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection*

Investigation of the mechanisms whereby nonpeptidic, low molecular weight CCR5 ligands block HIV-1 entry and infection suggests that allosteric C CR5 inhibitors not only act by blocking gp120 binding but also alter distinct steps of CCR4 usage in the course of HIV infection.

Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue

Results show that a limited amino acid sequence is responsible for SCH-C specificity to CCR5, and propose a model showing the interaction with C CR5 Ile198, and show that understanding receptor/drug interactions facilitates drug design.
...

References

SHOWING 1-10 OF 48 REFERENCES

Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5

It is suggested that, together with molecular models of the interactions between the drugs and CCR5, the inhibitory activity of TAK-220 could involve direct interactions with amino acid residues in TMs 4, 5, and 6 in addition to those in the previously postulated binding pocket.

Structural and Molecular Interactions of CCR5 Inhibitors with CCR5*

Structural and molecular interactions of CC-chemokine receptor 5 with three CCR5 inhibitors active against R5 human immunodeficiency virus type 1 (HIV-1) including the potent in vitro and in vivo aplaviroc (AVC) are characterized to help design more potent and more HIV-1-specific C CR5 inhibitors.

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

  • T. DragicA. Trkola J. Moore
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2000
HIV-1 entry into CD4(+) cells requires the sequential interactions of the viral envelope glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCR5 and CXCR4 to be blocked, and the TAK-779 molecule is explored.

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

  • M. BabaO. Nishimura M. Fujino
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TAK-779 displayed highly potent and selective inhibition of R5 HIV-1 replication without showing any cytotoxicity to the host cells, and the inhibition of beta-chemokine receptors appeared to be specific to CCR5.

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry

The mechanism of action of two inhibitors of CCR5 function are identified, SCH-350581 (AD101) and SCH-351125 (SCH-C), which are more potent than SCH-C at inhibiting HIV-1 replication in primary lymphocytes, as well as viral entry and gp120 binding to cell lines.

The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.

Naturally Occurring CCR5 Extracellular and Transmembrane Domain Variants Affect HIV-1 Co-receptor and Ligand Binding Function*

Data demonstrate that single amino acid changes in the extracellular domains of CCR5 can have profound effects on both HIV-1 co-receptor and specific ligand-induced functions, whereas mutations in the transmembrane domain only affect the response to chemokine ligands.

Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro

A novel spirodiketopiperazine (SDP) derivative, AK602, which specifically blocked the binding of macrophage inflammatory protein 1α (MIP-1α) to CCR5 with a high affinity, potently blocked human immunodeficiency virus type 1 (HIV-1) gp120/CCR5 binding and exerted potent activity against a wide spectrum of laboratory and primary R5 HIV-1 isolates.

Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists

It was showed that glutamate 291 (Glu291) of CCR2 is a critical residue for high affinity binding and that this residue contributes little to MCP-1 binding to CCR1, a member of the G-protein-coupled seven-transmembrane receptor superfamily.